From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients.
This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing.
Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy.
This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Manfred Dietel erhielt nach dem Medizinstudium an der Universität Hamburg und seiner weiteren wissenschaftlichen Ausbildung am Institut für Pathologie des Universitäts-Krankenhauses Hamburg Eppendorf dort eine Professur für das Fach 'Pathologie und Pathologische Anatomie' im Fachbereich Medizin der Universität Hamburg. Mit seiner Berufung zum ordentlichen Professor wurde er 1989 Direktor des Instituts für Allgemeine Pathologie der Christian-Albrechts-Universität zu Kiel und wechselte 1993 in seine jetzige Stellung als Direktor des Instituts für Pathologie der Charité, Rudolf-Virchow-Haus, Humboldt-Universität zu Berlin. Er war und ist in der akademischen Selbstverwaltung u.a. tätig als Dekan der Medizinischen Fakultät der Charité der Humboldt-Universität, Mitglied des Wissenschaftlichen Beirats der Bundesärztekammer, Ärztlicher Direktor und Vorsitzender des Vorstandes der Charité und Mitglied des Medizinausschuss des Wissenschaftsrats. Aktuell ist Professor Dietel Vorsitzender des Vorstands der Deutschen Gesellschaft für Pathologie und Mitglied des Vorstands der Deutschen Gesellschaft für Senologie und der Deutschen Gesellschaft für Telemedizin. Dietels wissenschaftliches Interesse gilt insbesondere der molekularen Tumorpathologie mit Untersuchungen zur Zytostatikaresistenz, prädiktiven Testung zum therapeutischen Ansprechen maligner Tumore und zu tumorassoziierten genetischen Veränderungen (mol. Biomarker). Weitere Schwerpunkte sind neue Verfahren in der histologischen Diagnostik maligner Tumoren (spez. Gynäkopathologie) und die technische Entwicklung von Telepathologiesystemen. Sein Fokus in Krankenversorgung und Lehre sind die histologische Diagnostik an operativ oder endoskopisch entnommenem Gewebsmaterial (in vivo-Diagnostik).
From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body¿s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients. This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing. Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy. This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Brook Bookstore On Demand, Napoli, NA, Italien
Zustand: new. Questo è un articolo print on demand. Bestandsnummer des Verkäufers e00cd23a3e4971be20b58a2b9734ad9e
Anzahl: Mehr als 20 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -From its introduction, oncological chemotherapy has been encumbered by poor selectivity because antiproliferative drugs are often toxic not only to tumor cells but also to important populations of the body's non-neoplastic cells. Modern targeted therapies interact with defined molecules present on cancer cells, adding increased selectivity to their toxic effects. This book presents an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach. 280 pp. Englisch. Bestandsnummer des Verkäufers 9783642432439
Anzahl: 2 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 23055607
Anzahl: 15 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: New. Bestandsnummer des Verkäufers 23055607-n
Anzahl: 15 verfügbar
Anbieter: California Books, Miami, FL, USA
Zustand: New. Bestandsnummer des Verkäufers I-9783642432439
Anzahl: Mehr als 20 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Traces progress in the development of new chemotherapy agentsExplores methods for detecting target molecules on tumors to create more selective chemo drugsPresents an integrated critical view of the theories, mechanisms, problems and pitfal. Bestandsnummer des Verkäufers 5060661
Anzahl: Mehr als 20 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body's non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients.This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing.Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy. This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach. Bestandsnummer des Verkäufers 9783642432439
Anzahl: 1 verfügbar
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Targeted Therapies in Cancer | Manfred Dietel | Taschenbuch | Recent Results in Cancer Research | xiv | Englisch | 2014 | Springer | EAN 9783642432439 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Bestandsnummer des Verkäufers 104983613
Anzahl: 5 verfügbar
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body¿s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients.This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing.Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy.This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 280 pp. Englisch. Bestandsnummer des Verkäufers 9783642432439
Anzahl: 1 verfügbar
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Paperback. Zustand: Brand New. 2007 edition. 280 pages. 9.70x6.70x0.64 inches. In Stock. Bestandsnummer des Verkäufers x-3642432433
Anzahl: 2 verfügbar